Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

330 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and Tolerability of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart (NovoLog) When Used in Insulin Pumps in Adults with Type 1 Diabetes: A Randomized, Open-Label Clinical Trial.
Thrasher J, Polsky S, Hovsepian L, Nowotny I, Pierre S, Bois De Fer B, Bhargava A, Mukherjee B, Garg SK. Thrasher J, et al. Among authors: pierre s. Diabetes Technol Ther. 2020 Sep;22(9):666-673. doi: 10.1089/dia.2019.0446. Epub 2020 Jan 28. Diabetes Technol Ther. 2020. PMID: 31833801 Free PMC article. Clinical Trial.
Efficacy, Safety, and Immunogenicity of Insulin Aspart Biosimilar SAR341402 Compared with Originator Insulin Aspart in Adults with Diabetes (GEMELLI 1): A Subgroup Analysis by Prior Type of Mealtime Insulin.
Shah VN, Franek E, Wernicke-Panten K, Pierre S, Mukherjee B, Sadeharju K. Shah VN, et al. Among authors: pierre s. Diabetes Ther. 2021 Feb;12(2):557-568. doi: 10.1007/s13300-020-00992-x. Epub 2021 Jan 11. Diabetes Ther. 2021. PMID: 33432547 Free PMC article.
Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 Versus Originator Insulin Aspart Mix 70/30 (NovoMix 30) in People with Diabetes: A 26-Week, Randomized, Open-Label Trial (GEMELLI M).
Aravind SR, Singh KP, Aquitania G, Mogylnytska L, Zalevskaya AG, Matyjaszek-Matuszek B, Wernicke-Panten K, Nguyên-Pascal ML, Pierre S, Rotthaeuser B, Kramer D, Mukherjee B. Aravind SR, et al. Among authors: pierre s. Diabetes Ther. 2022 May;13(5):1053-1071. doi: 10.1007/s13300-022-01255-7. Epub 2022 Apr 14. Diabetes Ther. 2022. PMID: 35420397 Free PMC article.
Efficacy, Safety, and Immunogenicity of Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 Compared with Originator Insulin Aspart Mix 70/30 in Adults with Diabetes (GEMELLI M): A Subgroup Analysis by Prior Type of Premix Insulin.
Aravind SR, Singh KP, Mogylnytska L, Zalevskaya AG, Matyjaszek-Matuszek B, Wernicke-Panten K, Nguyên-Pascal ML, Pierre S, Rotthaeuser B, Kramer D, Mukherjee B. Aravind SR, et al. Among authors: pierre s. Diabetes Ther. 2022 Jul;13(7):1299-1310. doi: 10.1007/s13300-022-01279-z. Epub 2022 Jun 1. Diabetes Ther. 2022. PMID: 35650350 Free PMC article.
Pharmacokinetic similarity of switching SAR341402 insulin aspart biosimilar and NovoLog insulin aspart versus continuous use of NovoLog in adults with type 1 diabetes: The GEMELLI X trial.
Shah VN, Al-Karadsheh A, Barnes C, Mandry J, Nakhle S, Wernicke-Panten K, Kramer D, Schmider W, Pierre S, Teichert L, Rotthaeuser B, Mukherjee B, Bailey TS. Shah VN, et al. Among authors: pierre s. Diabetes Obes Metab. 2024 Feb;26(2):540-547. doi: 10.1111/dom.15341. Epub 2023 Oct 25. Diabetes Obes Metab. 2024. PMID: 37880868 Clinical Trial.
Safety and Efficacy of Switching SAR341402 Insulin Aspart and Originator Insulin Aspart vs Continuous Use of Originator Insulin Aspart in Adults With Type 1 Diabetes: The GEMELLI X Trial.
Shah VN, Al-Karadsheh A, Barnes C, Mandry J, Nakhle S, Wernicke-Panten K, Kramer D, Schmider W, Pierre S, Teichert L, Rotthaeuser B, Mukherjee B, Bailey TS. Shah VN, et al. Among authors: pierre s. J Diabetes Sci Technol. 2024 Feb 29:19322968241232709. doi: 10.1177/19322968241232709. Online ahead of print. J Diabetes Sci Technol. 2024. PMID: 38420944 Free PMC article.
330 results